The Goldman Sachs Group Boosts Natera (NASDAQ:NTRA) Price Target to $100.00

Natera (NASDAQ:NTRA) had its price objective hoisted by The Goldman Sachs Group from $90.00 to $100.00 in a research note released on Monday morning, Benzinga reports. The Goldman Sachs Group currently has a buy rating on the medical research company’s stock.

NTRA has been the subject of several other reports. Craig Hallum began coverage on shares of Natera in a research report on Monday, April 8th. They set a buy rating and a $117.00 target price for the company. Stephens reissued an overweight rating and set a $78.00 target price on shares of Natera in a research report on Tuesday, January 30th. BTIG Research boosted their price target on shares of Natera from $75.00 to $85.00 and gave the stock a buy rating in a report on Friday, December 29th. Raymond James cut shares of Natera from a strong-buy rating to an outperform rating and boosted their price target for the stock from $68.00 to $85.00 in a report on Tuesday, February 20th. Finally, Canaccord Genuity Group boosted their price target on shares of Natera from $87.00 to $100.00 and gave the stock a buy rating in a report on Thursday, February 29th. One analyst has rated the stock with a sell rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of Moderate Buy and an average target price of $86.40.

Natera Stock Up 0.0 %

Shares of NASDAQ NTRA opened at $90.33 on Monday. The company has a debt-to-equity ratio of 0.37, a current ratio of 4.10 and a quick ratio of 3.96. The company has a 50-day moving average price of $85.39 and a 200-day moving average price of $65.41. The stock has a market capitalization of $10.91 billion, a P/E ratio of -23.83 and a beta of 1.37. Natera has a 1 year low of $36.90 and a 1 year high of $98.82.

Natera (NASDAQ:NTRA) last posted its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.09. The company had revenue of $311.11 million during the quarter, compared to the consensus estimate of $300.38 million. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. On average, equities research analysts forecast that Natera will post -2.35 EPS for the current fiscal year.

Insider Activity

In other news, CEO Steven Leonard Chapman sold 1,958 shares of the business’s stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $68.16, for a total value of $133,457.28. Following the sale, the chief executive officer now owns 175,550 shares of the company’s stock, valued at $11,965,488. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, CEO Steven Leonard Chapman sold 1,958 shares of the company’s stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $68.16, for a total transaction of $133,457.28. Following the sale, the chief executive officer now owns 175,550 shares of the company’s stock, valued at approximately $11,965,488. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Daniel Rabinowitz sold 35,307 shares of the company’s stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $75.09, for a total transaction of $2,651,202.63. Following the sale, the insider now directly owns 204,218 shares in the company, valued at approximately $15,334,729.62. The disclosure for this sale can be found here. Insiders have sold a total of 453,293 shares of company stock valued at $36,453,056 over the last quarter. Company insiders own 9.42% of the company’s stock.

Institutional Trading of Natera

Hedge funds and other institutional investors have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC increased its holdings in Natera by 28.6% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 720,160 shares of the medical research company’s stock worth $45,111,000 after acquiring an additional 159,993 shares during the period. WCM Investment Management LLC increased its holdings in shares of Natera by 101.2% in the 4th quarter. WCM Investment Management LLC now owns 145,996 shares of the medical research company’s stock worth $9,058,000 after buying an additional 73,419 shares during the last quarter. Aigen Investment Management LP bought a new position in shares of Natera in the 3rd quarter worth $223,000. Sei Investments Co. boosted its stake in shares of Natera by 33.4% in the 3rd quarter. Sei Investments Co. now owns 374,004 shares of the medical research company’s stock valued at $16,550,000 after purchasing an additional 93,556 shares in the last quarter. Finally, Banque Pictet & Cie SA boosted its stake in shares of Natera by 7.3% in the 3rd quarter. Banque Pictet & Cie SA now owns 142,850 shares of the medical research company’s stock valued at $6,321,000 after purchasing an additional 9,755 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.